363 related articles for article (PubMed ID: 35266095)
1. A case of COVID-19 reinfection in a hemodialysis patient: the role of antibody in SARS-CoV-2 infection.
Beppu H; Ogawa T; Ishikane M; Kawanishi T; Fukuda T; Sato L; Matsunaga A; Maeda K; Katagiri D; Ishizaka Y; Mitsuya H; Ohmagari N; Yasui F; Kohara M; Kikuchi K; Wakai S
CEN Case Rep; 2022 Nov; 11(4):422-427. PubMed ID: 35266095
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC
Inada M; Ishikane M; Terada M; Matsunaga A; Maeda K; Tsuchiya K; Miura K; Sairenji Y; Kinoshita N; Ujiie M; Kutsuna S; Ishizaka Y; Mitsuya H; Ohmagari N
J Infect Chemother; 2021 Jul; 27(7):1063-1067. PubMed ID: 33962861
[TBL] [Abstract][Full Text] [Related]
3. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
[TBL] [Abstract][Full Text] [Related]
4. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
5. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection of a Healthcare Worker in a Belgian Nosocomial Outbreak Despite Primary Neutralizing Antibody Response.
Selhorst P; van Ierssel SH; Michiels J; Mariën J; Bartholomeeusen K; Dirinck E; Vandamme S; Jansens H; Ariën KK
Clin Infect Dis; 2021 Nov; 73(9):e2985-e2991. PubMed ID: 33315049
[TBL] [Abstract][Full Text] [Related]
7. Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.
Schuler CF; Gherasim C; O'Shea K; Manthei DM; Chen J; Zettel C; Troost JP; Kennedy AA; Tai AW; Giacherio DA; Valdez R; Baldwin JL; Baker JR
Microbiol Spectr; 2021 Oct; 9(2):e0008721. PubMed ID: 34468184
[TBL] [Abstract][Full Text] [Related]
8. Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade.
Masiá M; Fernández-González M; García JA; Padilla S; García-Abellán J; Botella Á; Mascarell P; Agulló V; Gutiérrez F
EBioMedicine; 2022 Aug; 82():104153. PubMed ID: 35816896
[TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulins using chemiluminescence immunoassay and its correlation with neutralizing antibodies.
Gaber Y; Abdel Alem S; Musa S; Amer K; Elnagdy T; Hassan WA; Abdelrahman RZ; Gad A; Ali MA; Badary HA; Shawky S; Talaat H; Kassem AM; Fouad R
Virus Res; 2022 Oct; 319():198852. PubMed ID: 35834979
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Spike-Binding Antibody Longevity and Protection from Reinfection with Antigenically Similar SARS-CoV-2 Variants.
Kubale J; Gleason C; Carreño JM; Srivastava K; Singh G; ; Gordon A; Krammer F; Simon V
mBio; 2022 Oct; 13(5):e0178422. PubMed ID: 35997286
[TBL] [Abstract][Full Text] [Related]
11. A stronger antibody response in increased disease severity of SARS-CoV-2.
de Oliveira MI; Aciole MR; Neves PAF; Silva VPOE; Silva MPOE; de Lorena VMB; de Araújo PSR
BMC Infect Dis; 2024 Jan; 24(1):17. PubMed ID: 38166763
[TBL] [Abstract][Full Text] [Related]
12. Generation and persistence of S1 IgG and neutralizing antibodies in post-COVID-19 patients.
Guzmán-Martínez O; Guardado K; Varela-Cardoso M; Trujillo-Rivera A; Marín-Hernández A; Ortiz-León MC; Gómez-Ñañez I; Gutiérrez M; Espinosa R; Sampieri CL; Ramos C; López-Guerrero DV; Zenteno-Cuevas R; Pérez-Carreón JI; Canales-Vázquez G; Montero H
Infection; 2022 Apr; 50(2):447-456. PubMed ID: 34668145
[TBL] [Abstract][Full Text] [Related]
13. A case with SARS-CoV-2 reinfection from India.
Munivenkatappa A; Sahay RR; Deshpande GR; Patil DY; Shete AM; Sapkal GN; Kumar R; Narayana M; Yadav PD; Shettar V
Indian J Med Microbiol; 2022; 40(1):166-168. PubMed ID: 34789389
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
15. The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China.
Chu J; Dai Q; Dong C; Kong X; Tian H; Li C; Peng J; Xu K; Ju H; Bao C; Hu J; Zhu L
Front Public Health; 2024; 12():1364048. PubMed ID: 38873290
[TBL] [Abstract][Full Text] [Related]
16. Antibody Status, Disease History, and Incidence of SARS-CoV-2 Infection Among Patients on Chronic Dialysis.
Cohen DE; Sibbel S; Marlowe G; Bludorn K; Miller D; Kelley T; Connaire J; Young A; Tentori F; Brunelli SM
J Am Soc Nephrol; 2021 Aug; 32(8):1880-1886. PubMed ID: 34215666
[TBL] [Abstract][Full Text] [Related]
17. Hemodialysis patients with coronavirus disease 2019: reduced antibody response.
Beppu H; Fukuda T; Kawanishi T; Yasui F; Toda M; Kimura H; Nakamura Y; Nakamura Y; Kojima K; Ogawa H; Ishiwatari A; Kamei Y; Ogawa T; Abe Y; Endo M; Hanawa T; Mizobuchi R; Sugita C; Okamoto K; Hatakeyama S; Yamada T; Kohara M; Wakai S
Clin Exp Nephrol; 2022 Feb; 26(2):170-177. PubMed ID: 34487276
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
19. Anti-SARS-CoV-2 IgG and Neutralizing Antibody Levels in Patients with Past COVID-19 Infection: A Longitudinal Study.
Dinç HÖ; Demirci M; Özdemir YE; Sirekbasan S; Aktaş AN; Karaali R; Tuyji Tok Y; Özbey D; Akçin R; Gareayaghi N; Kuşkucu MA; Midilli K; Aygün G; Sarıbaş S; Kocazeybek B
Balkan Med J; 2022 May; 39(3):172-177. PubMed ID: 35378574
[TBL] [Abstract][Full Text] [Related]
20. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.
Semmler G; Traugott MT; Graninger M; Hoepler W; Seitz T; Kelani H; Karolyi M; Pawelka E; Aragón de La Cruz S; Puchhammer-Stöckl E; Aberle SW; Stiasny K; Zoufaly A; Aberle JH; Weseslindtner L
J Clin Microbiol; 2021 Apr; 59(5):. PubMed ID: 33602698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
